Glenmark gets USFDA nod for Diltiazem HCL ER capsules

This is the generic version of Cardizem1 SR extended release capsules, 60 mg, 90 mg, and 120 mg, of Biovail Laboratories.

69
USFDA
Picture: Pixabay

Last Updated on March 24, 2021 by The Health Master

Glenmark Pharmaceuticals has received final approval by the United States Food and Drug Administration (USFDA) for diltiazem hydrochloride extended release capsules USP, 60 mg, 90 mg, and 120 mg.

This is the generic version of Cardizem1 SR extended release capsules, 60 mg, 90 mg, and 120 mg, of Biovail Laboratories.

Medicine Capsule
Picture: Unsplash

Glenmark has been granted a competitive generic therapy (CGT) designation for Diltiazem hydrochloride extended release capsules USP, 60 mg, 90 mg, and 120 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing.

According to IQVIATM sales data for the 12 month period ending January 2021, the Cardizem SR extended release capsules, 60 mg, 90 mg, and 120 mg market achieved annualsales of approximately
$56.7 million.

Glenmark’s current portfolio consists of 170 products authorised for distribution in the US marketplace and 42 ANDA’s pending approval with the USFDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Also read related news:

Strides gets USFDA nod for Potassium Chloride for oral solution

Pharma Companies recall these drugs in US

AstraZeneca gets DCGI approval for Osimertinib tablets

Lupin launches generic Nitazoxanide tablets

Dr Reddy’s gets 3 observations from USFDA for US-based API plant

World’s most expensive drug, costs ₹18 crore per dose

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner